INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company specializing in creating simplified, affordable treatments and commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell, for patients diagnosed with infertility, will report financial results for its first quarter 2021, completed on March 31, 2021, after the market close on May 17th. INVO stock price soared adjacent to the news.
At last check-in after-market trading, shares of INVO Bioscience Inc. (INVO) were up 2.43% at $3.8. INVO’s stock closed the last session at $3.71, decreasing -1.07% or -$0.04. Shares of the company fluctuated between $3.60 and $3.74 throughout the day.INVO shares have fallen by -38.33% over the last 12 months, and they have moved down by -4.63% in the past week.
About INVO Bioscience, Inc.
INVO Bioscience, Inc has also initiated the execution of a partnership agreement with Lyfe Medical, with the objective to expand the INVOcell solution in Northern California which consists of an area population of approximately 8 million people.
In accordance with the partnership agreement, Lyfe Medical will set up and utilize a clinic in the San Francisco Bay Area which will offer the INVO procedure to the relevant patients, and INVO Bioscience will set up and utilize the embryology center which will offer laboratory services in connection with the INVO procedure put forward by Lyfe Medical to its patients.
About Lyfe Medical
Lyfe Medical is part of the Tribeca Company. Tribeca Companies is a global life-science conglomerate that specializes in the fields of diagnostics, next-generation medical devices, direct physician to patient care services, and technology-enabled solutions. The company also focuses on delivering industry-leading expertise in the field of medical science to its target patients and partners.
Lyfe Medical is a doctor-led premier-level fertility practice focused on the delivery of incredible patient care and treatment results. The company objectives include a dedication for success in results. The core mission is inclusive of increasing access to fertility services, establishing a relationship with the patient, and an emphasis on the treatment of infertility.
A lucrative partnership established with Lyfe Medical combined with commercializing products that may tackle infertility and potential for a positive financial result in May 17th has increased investor expectation for the company with INVO stock price rising at last check.